FreeRx
Dolutegravir Tablets
Dolutegravir Sodium
Target markets: Africa, SE Asia
FormulationsFreely Exportable
Sofosbuvir + Velpatasvir Tablets
Sofosbuvir 400 mg + Velpatasvir 100 mg
WHO-GMP Partner-Manufactured
Target: SE Asia, LatAm, Africa
Regulatory-Aware Support
Reliable Supply Chain
Product Overview
A pan-genotypic direct-acting antiviral combination for chronic hepatitis C. One of India's landmark generic export successes, available under voluntary licensing arrangements across many licence territories.
Key Points
- Pan-genotypic hepatitis C direct-acting antiviral
- Available under voluntary licence in many territories — territory confirmed before quoting
- WHO-GMP partner-manufactured
Quick Specifications
| Generic Name | Sofosbuvir 400 mg + Velpatasvir 100 mg |
|---|---|
| Dosage Form | Tablet |
| Strength | 400 mg / 100 mg |
| HS Code | 3004.90 |
| Packaging | Bottles (28s), institutional bulk packs |
| MOQ | MOQ on request |
| Shelf Life | 24 months, batch-dependent |
| Storage | Store below 30°C |
Regulatory Information
Schedule H — Prescription Only
Schedule H — B2B export only. Voluntary licence territory is confirmed for the destination country before any quotation is issued.
View Antivirals — Hepatitis, Herpes, Influenza class detailsRequirements vary by destination. Verify current requirements with the relevant authority before shipment. See our Compliance page.
Need documentation first?
Our team can share a product brochure and manufacturing-partner regulatory summary on request — just mention it in your enquiry.